Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619515 · ClinicalTrials.gov registry record · NA
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
A NA study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 73
- Enrollment target
NCT00619515: Clinical Trial NA study, sponsored by Case Comprehensive Cancer Center.
NCT00619515 is a NA study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 73 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00619515, a NA study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
Study Summary
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This trial is studying the side effects of stereotactic radiation therapy and to see how well it works in treating patients with prostate cancer.
Primary Outcome
This study's primary goal is to determine the rate of acute grade 3-5 toxicities following CyberKnife treatment. Per RTOG/ECOG, acute toxicity will be defined as occurring within 90 days of completing treatment.
Interventions
- OTHER questionnaire administration
- RADIATION stereotactic radiosurgery
- PROCEDURE implanted fiducial-based imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-02 |
| Phase | NA |
Why NCT00619515 stopped before completion
NCT00619515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which questionnaire administration is the first listed.
NCT00619515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00619515 about?
NCT00619515 is a clinical study titled "Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This trial is studying the side effects of stereotactic radiation therapy and to see how well it works in treating patients with prostate cancer.
What is the current status of trial NCT00619515?
This trial is currently terminated. It is a NA study. The enrollment target is 73 participants. The study started on 2007-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00619515?
The interventions under investigation include: questionnaire administration (OTHER), stereotactic radiosurgery (RADIATION), implanted fiducial-based imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00619515?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00619515's enrollment target sits among peer trials
73 1089th of 2000 higher than 912 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia